SCHEMBL651022

SCHEMBL651022

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccc(OC(C)=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.45
CNR2 P34972 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
TSHR P16473 3/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
ACHE P22303 1/20 0.37
BACE1 P56817 1/20 0.36
GNRHR P30968 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072450 0.95 C5AR1 (0.47) C5AR1TSHRALDH1A1KDM4EGAA
SCHEMBL651365 0.92 C5AR1 (0.46) C5AR1CNR2TSHRALDH1A1LMNA
SCHEMBL5072205 0.91 C5AR1 (0.46) C5AR1CNR2TSHRALDH1A1LMNA
SCHEMBL4770818 0.90 TAS2R14 (0.43) C5AR1CNR2LTB4R2IRAK4ALDH1A1
SCHEMBL5136291 0.90 C5AR1 (0.45) C5AR1CNR2TSHRALDH1A1LMNA
SCHEMBL647835 0.89 C5AR1 (0.42) C5AR1KDM4E
SCHEMBL5136578 0.89 C5AR1 (0.43) C5AR1CNR2LTB4R2TSHRALDH1A1
SCHEMBL5134952 0.89 C5AR1 (0.44) C5AR1CNR2TSHRALDH1A1LMNA
SCHEMBL5136185 0.89 C5AR1 (0.44) C5AR1CNR2TSHRALDH1A1LMNA
SCHEMBL5135582 0.88 ATP4A (0.44) C5AR1TSHRALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed